Direct Flow Medical Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) in April to broaden its SALUS Trial. The expansion includes the addition of high-risk patients and randomization against a commercial device, the Medtronic CoreValve.

Two companion papers published in Academic Emergency Medicine address the question of when it is appropriate to discharge patients experiencing a potentially fatal blood clot. The studies particularly focus on patients presenting with low-risk deep vein thrombosis (DVT) or pulmonary embolism (PE).

Veryan Medical announced that the first subject has been enrolled in their MIMICS-2 study at Universitäts-Herzzentrum Freiburg in Bad Krozingen, Germany by the European principal investigator, Prof. Thomas Zeller.

Medtronic plc announced the first in-office implant of its miniaturized cardiac monitor as part of the Medtronic Reveal LINQ In-Office 2 (RIO 2) Study. One of the world's smallest cardiac monitors, the Reveal LINQ insertable cardiac monitor (ICM) was successfully implanted in an office setting at Scripps Clinic in La Jolla, California, by cardiologist John Rogers, M.D. The RIO 2 study will determine if the procedure, performed in an in-office setting, is as safe as procedures performed in a traditional hospital setting — such as an operating room, cardiac catheterization laboratory or electrophysiology laboratory.